A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, ...

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...